DK2180787T3 - Nitrooliesyremodulering af type ii-diabetes - Google Patents
Nitrooliesyremodulering af type ii-diabetesInfo
- Publication number
- DK2180787T3 DK2180787T3 DK08780348.2T DK08780348T DK2180787T3 DK 2180787 T3 DK2180787 T3 DK 2180787T3 DK 08780348 T DK08780348 T DK 08780348T DK 2180787 T3 DK2180787 T3 DK 2180787T3
- Authority
- DK
- Denmark
- Prior art keywords
- nitroolic
- diabetes
- type
- acid modulation
- modulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95336007P | 2007-08-01 | 2007-08-01 | |
PCT/US2008/009274 WO2009017802A1 (en) | 2007-08-01 | 2008-08-01 | Nitro-fattyacid modulation of type ii diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2180787T3 true DK2180787T3 (da) | 2014-02-03 |
Family
ID=40304683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08780348.2T DK2180787T3 (da) | 2007-08-01 | 2008-08-01 | Nitrooliesyremodulering af type ii-diabetes |
Country Status (4)
Country | Link |
---|---|
US (8) | US8324277B2 (da) |
EP (2) | EP2679224A1 (da) |
DK (1) | DK2180787T3 (da) |
WO (1) | WO2009017802A1 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3410371B2 (ja) * | 1998-08-18 | 2003-05-26 | リンテック株式会社 | ウエハ裏面研削時の表面保護シートおよびその利用方法 |
US7776916B2 (en) | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
US8324277B2 (en) | 2007-08-01 | 2012-12-04 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
CA2729053A1 (en) | 2008-05-01 | 2009-11-05 | Bruce A. Freeman | Vinyl substituted fatty acids |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
CN102099024B (zh) | 2008-06-19 | 2015-11-25 | 犹他大学研究基金会 | 硝化脂质在毒性医疗疗法的副作用的治疗上的用途 |
US8933255B2 (en) * | 2008-12-31 | 2015-01-13 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
JP2013500966A (ja) | 2009-07-31 | 2013-01-10 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 抗炎症剤としての脂肪酸 |
EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
WO2011089265A1 (en) | 2010-01-25 | 2011-07-28 | Bridge Bioresearch Plc | Use of fatty acid compounds for lowering blood glucose levels |
CN102843922B (zh) | 2010-05-13 | 2015-12-16 | 尼特罗米加公司 | 硝基脂肪酸–认知减退的神经保护和/或抑制 |
JP2013534930A (ja) * | 2010-06-28 | 2013-09-09 | コンプレクサ,インコーポレイテッド | 糖尿病を治療するための多成分調剤 |
EP2744491B1 (en) | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
DK3303339T3 (da) | 2015-07-07 | 2021-04-12 | H Lundbeck As | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme |
EP3355879A4 (en) | 2015-10-02 | 2019-05-22 | Complexa, Inc. | PREVENTION, TREATMENT AND INVERSION OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS |
CN109071405A (zh) | 2016-03-04 | 2018-12-21 | 高等教育联邦系统-匹兹堡大学 | 使用治疗有效量的二羧酸化合物预防、治疗和逆转疾病 |
JP2019529501A (ja) | 2016-10-05 | 2019-10-17 | ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションUniversity Of Pittsburgh Of The Commonwealth System Of Higher Education | 可逆的に保護された、チオレート化求電子性脂肪酸としてのプロドラッグ |
CA3039030A1 (en) * | 2016-10-05 | 2018-04-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Novel reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions |
JP2021526134A (ja) | 2018-05-25 | 2021-09-30 | イマラ インク. | 6−[(3S,4S)−4−メチル−l−(ピリミジン−2−イルメチル)ピロリジン−3−イル]−3−テトラヒドロピラン−4−イル−7H−イミダゾ[l,5−A]ピラジン−8−オンの一水和物および結晶形態 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB587992A (en) | 1944-12-11 | 1947-05-12 | Charles William Scaife | Improvements in and relating to the production of organic nitrogen compounds |
US3578687A (en) | 1968-01-30 | 1971-05-11 | Texaco Inc | Process for producing 4-nitroalkanoic acids |
US3819561A (en) | 1970-10-23 | 1974-06-25 | Aerojet General Co | Wetting agents for non-aqueous dispersions |
JPS5313608B2 (da) | 1972-06-16 | 1978-05-11 | ||
JPS5318013B2 (da) | 1973-03-19 | 1978-06-13 | ||
US4599430A (en) | 1981-12-21 | 1986-07-08 | The Standard Oil Company | Nitrogenation of hydrocarbons, including the production of maleimide |
JPS62132804A (ja) | 1985-12-05 | 1987-06-16 | Aguro Kanesho Kk | 植物生長調節剤 |
US5412137A (en) | 1993-06-07 | 1995-05-02 | Sandoz Ltd. | Process for preparing phosphinyloxy propanaminium inner salt derivatives |
JPH10507179A (ja) | 1994-10-13 | 1998-07-14 | ペプチド テクノロジー リミテッド | 修飾ポリ不飽和脂肪酸 |
US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
GB9618420D0 (en) | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
US6187747B1 (en) * | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
EP1025842B1 (en) | 1997-10-30 | 2004-07-21 | Morishita Jintan Co., Ltd. | Double-leyered capsule of unsaturated fatty acid or derivative thereof and process for producing the same |
WO2000009075A2 (en) | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
EP1204626B1 (en) | 1999-04-01 | 2008-01-16 | Esperion Therapeutics Inc. | Ether compounds, compositions, and uses thereof |
WO2001006983A2 (en) | 1999-07-22 | 2001-02-01 | Incell Corporation, Llc | Fatty acids to minimize cancer therapy side effects |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
AUPQ291499A0 (en) | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
US6346231B1 (en) | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
US20010037598A1 (en) | 1999-12-14 | 2001-11-08 | Suppes Galen J. | Process for producing cetane improvers from triglycerides |
AU3846801A (en) | 2000-02-16 | 2001-08-27 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
AR032318A1 (es) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
AR034120A1 (es) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico |
AR030416A1 (es) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA |
PT1294658E (pt) | 2000-06-28 | 2005-07-29 | Zambon Spa | Processo para a preparacao de nitroalcenos |
AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
SK12772003A3 (sk) | 2001-04-18 | 2004-07-07 | Prometic Biosciences Inc. | Stredne dlhé mastné kyseliny, glyceridy a analógy ako faktory prežitia a aktivácie neutrofilov |
US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
JPWO2002102364A1 (ja) | 2001-06-18 | 2004-09-30 | 山田 幸子 | PPARγ作動性医薬組成物 |
AU2002331618B2 (en) | 2001-08-17 | 2007-11-01 | University Of Pittsburgh | Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
GB0123961D0 (en) | 2001-10-05 | 2001-11-28 | Astrazeneca Ab | Process and intermediates |
WO2003039533A1 (en) | 2001-11-06 | 2003-05-15 | The Brigham And Women's Hospital, Inc. | Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
AU2003258909B2 (en) * | 2002-08-20 | 2010-07-08 | Philera New Zealand Limited | Dosage forms and related therapies |
US20040092590A1 (en) | 2002-09-27 | 2004-05-13 | Linda Arterburn | Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2005016864A1 (en) | 2003-07-29 | 2005-02-24 | The Arizona Disease Control Research Commission | Conjugated nitro alkene anticancer agents based on isoprenoid metabolism |
US20050136103A1 (en) | 2003-09-17 | 2005-06-23 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
US20090215895A1 (en) | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
US8241670B2 (en) | 2004-04-15 | 2012-08-14 | Chiasma Inc. | Compositions capable of facilitating penetration across a biological barrier |
US7776916B2 (en) | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
WO2006011397A1 (ja) | 2004-07-27 | 2006-02-02 | Kowa Company., Ltd. | 糖尿病の予防または治療のための薬剤 |
US7884131B2 (en) | 2004-11-19 | 2011-02-08 | Martek Biosciences, Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
US20070032420A1 (en) * | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
WO2008008767A2 (en) | 2006-07-14 | 2008-01-17 | Cedars-Sinai Medical Center | Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer |
RU2009101324A (ru) | 2006-07-19 | 2010-07-27 | Ризолвикс Фармасьютикалз, Инк. (Us) | Композиции и способы лечения воспаления слизистой оболочки |
EP2120920A4 (en) | 2007-02-20 | 2011-06-15 | Martek Biosciences Corp | OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE |
US8324277B2 (en) * | 2007-08-01 | 2012-12-04 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
CA2699483A1 (en) | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for modulating immune function |
CN103285394B (zh) | 2008-04-18 | 2016-01-20 | 犹他大学研究基金会 | 使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状 |
CA2729053A1 (en) | 2008-05-01 | 2009-11-05 | Bruce A. Freeman | Vinyl substituted fatty acids |
WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
CN102099024B (zh) | 2008-06-19 | 2015-11-25 | 犹他大学研究基金会 | 硝化脂质在毒性医疗疗法的副作用的治疗上的用途 |
ES2475065T3 (es) | 2008-10-09 | 2014-07-10 | Tekmira Pharmaceuticals Corporation | Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos |
US8937194B2 (en) | 2008-12-31 | 2015-01-20 | Nitromega Corp. | Topical compositions containing nitro fatty acids |
US8933255B2 (en) | 2008-12-31 | 2015-01-13 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
US20100286272A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications |
US20100286257A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging |
US20100286271A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Nitro-alkyl Compound Compositions |
KR20120046754A (ko) | 2009-07-29 | 2012-05-10 | 페노미넘 디스커버리스 인코포레이티드 | 히드록시 지방산 화합물 및 질병 치료 및 진단을 위한 그의 용도 |
JP2013500966A (ja) | 2009-07-31 | 2013-01-10 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 抗炎症剤としての脂肪酸 |
EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
CN102843922B (zh) | 2010-05-13 | 2015-12-16 | 尼特罗米加公司 | 硝基脂肪酸–认知减退的神经保护和/或抑制 |
JP2013534930A (ja) | 2010-06-28 | 2013-09-09 | コンプレクサ,インコーポレイテッド | 糖尿病を治療するための多成分調剤 |
EP2744491B1 (en) | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
JP2015508065A (ja) | 2012-02-03 | 2015-03-16 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 抗炎症薬としての脂肪酸 |
US8956541B2 (en) | 2012-06-18 | 2015-02-17 | Eco Verde Technologies, Inc. | Composition and method for retention of solvated compounds and ions |
WO2014204872A2 (en) | 2013-06-14 | 2014-12-24 | Complexa, Inc. | Composition and method for inhibition of pkng from mycobacterium tuberculosis |
-
2008
- 2008-08-01 US US12/670,951 patent/US8324277B2/en active Active
- 2008-08-01 WO PCT/US2008/009274 patent/WO2009017802A1/en active Application Filing
- 2008-08-01 DK DK08780348.2T patent/DK2180787T3/da active
- 2008-08-01 EP EP13179211.1A patent/EP2679224A1/en not_active Withdrawn
- 2008-08-01 EP EP08780348.2A patent/EP2180787B1/en active Active
-
2012
- 2012-11-01 US US13/666,827 patent/US8735449B2/en active Active
-
2014
- 2014-04-03 US US14/244,741 patent/US9186408B2/en not_active Expired - Fee Related
-
2015
- 2015-10-26 US US14/923,265 patent/US9700534B2/en active Active
-
2017
- 2017-06-21 US US15/629,277 patent/US10258589B2/en active Active
-
2019
- 2019-02-20 US US16/280,704 patent/US10576051B2/en active Active
-
2020
- 2020-01-21 US US16/748,453 patent/US10869850B2/en active Active
- 2020-11-17 US US16/950,805 patent/US20210220315A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160045467A1 (en) | 2016-02-18 |
US20180250257A9 (en) | 2018-09-06 |
US20210220315A1 (en) | 2021-07-22 |
EP2180787A1 (en) | 2010-05-05 |
US8324277B2 (en) | 2012-12-04 |
US20180125806A1 (en) | 2018-05-10 |
WO2009017802A9 (en) | 2014-12-04 |
US9700534B2 (en) | 2017-07-11 |
US10258589B2 (en) | 2019-04-16 |
US20130059912A1 (en) | 2013-03-07 |
US9186408B2 (en) | 2015-11-17 |
US10869850B2 (en) | 2020-12-22 |
EP2180787B1 (en) | 2013-10-30 |
US20200230095A1 (en) | 2020-07-23 |
EP2180787A4 (en) | 2010-09-01 |
US20100216884A1 (en) | 2010-08-26 |
WO2009017802A1 (en) | 2009-02-05 |
US20140309303A1 (en) | 2014-10-16 |
US10576051B2 (en) | 2020-03-03 |
US8735449B2 (en) | 2014-05-27 |
EP2679224A1 (en) | 2014-01-01 |
US20190274987A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2180787T3 (da) | Nitrooliesyremodulering af type ii-diabetes | |
DK3225251T3 (da) | Modulering af pro-neurotrofinaktivitet | |
DK2219469T3 (da) | Modificering af enzymatisk disponerede proteiner | |
DK2274417T3 (da) | Cellulær produktion af glucarsyre | |
DK2304911T3 (da) | Optisk signalmodulation | |
DK2317851T3 (da) | Anvendelse af 5-fluorcytosin som fungicid | |
DK2111555T3 (da) | Diagnosticering af præeklampsi | |
DE112007000789A5 (de) | Verwendung von Bora-tetraazepentalenen | |
DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener | |
BRPI0810660A2 (pt) | Derivados do ácido lipóico | |
DE602007011741D1 (de) | Optisches modulationselement | |
DK2272296T3 (da) | Ul/dl-planlægning til anvendelse af fuld båndbredde | |
DK2114147T3 (da) | Reduktion af bivirkninger af tramadol | |
BRPI0912547A2 (pt) | aba de fixação | |
DK2307441T3 (da) | Fremgangsmåde til fremstilling af insulinforbindelser | |
DK2231640T3 (da) | Beta-aminosyrederivater til behandling af diabetes | |
DK2245079T3 (da) | Klæbestof | |
DK2181065T3 (da) | Partialoxidation af carbonhydrider | |
DK2308860T3 (da) | Immunosuppressor baseret på afbrydelse af tcr-nck-interaktion | |
BRPI0918146A2 (pt) | corantes ácidos | |
DK2145547T3 (da) | Forbedret stabilitet af aromatiske forbindelser | |
DK2097079T3 (da) | Modulering af prostaglandin/cyclooxygenase-metabolske veje | |
DK2171083T3 (da) | Biosensing af molekylær konformation | |
DK2346485T3 (da) | Anvendelse af betain | |
DK200800145A (da) | Fremgangsmåde til fremstilling af etiketter |